AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small molecule Morphomers® with SupraAntigen® monoclonal antibodies, forming a new class of drug-candidates to target toxic proteins in CNS morADC demonstrated significant synergies, substantially increasing blood brain barrier penetration and potency to inhibit protein aggregation compared to the antibody or small molecule ...

Conference Call and Webcast Scheduled for August 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report second quarter 2024 financial results and provide a business update on August 7, 2024, after the close of the market. The announcement will b ...

GLEN ALLEN, Va., July 31, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the filing of a new patent application for AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defi ...

For the first quarter 2024, Celularity expects combined net sales of $14.8 million for its advanced biomaterial product and biobanking businesses, compared to the $10.25 million to $11.5 million guidance range previously announced in February. Celularity's expected combined net sales for the first half 2024 are $25.8 to $27.8 million compared to $6.9 million of net sales in the first of 2023 at the midpoint of the 2024 range. Celularity reiterated it is on track to file a 510(k) premarket submission for its ...

Location Primarily Dedicated to Manufacturing Company's New Pop & Go™ Freeze Pops Company Has Recently Added Three New Third Party Locations Dramatically Boosting Annual Capacity to Over 120 million Units LOS ANGELES, July 31, 2024 (GLOBE NEWSWIRE) -- Barfresh Food Group Inc. (the "Company" or "Barfresh") (NASDAQ:BRFH), a provider of frozen, ready-to-blend and ready-to-drink beverages, today announced a new co-manufacturing location. This new location will primarily be dedicated to manufacturing the Company ...

Company to host conference call after the market closes at 4:30 p.m. ET on Wednesday, August 14th GOLDEN, Colo., July 31, 2024 (GLOBE NEWSWIRE) -- SHF Holdings, Inc., d/b/a/ Safe Harbor Financial ("Safe Harbor" or the "Company") (NASDAQ:SHFS), a leader in facilitating financial services and credit facilities to the regulated cannabis industry, today announced that it will report financial results for the second quarter of 2024 ended June 30, 2024 on Wednesday, August 14, 2024 after the close of the market. ...

IRVING, Texas, July 31, 2024 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR), the world's leading company turning food waste into sustainable products and producer of renewable energy, today announced that its 50/50 joint venture Diamond Green Diesel (DGD) will provide the first regular supply of neat sustainable aviation fuel (SAF), to be blended with conventional jet fuel to create blended SAF, for commercial air travel out of John F. Kennedy International Airport (JFK) to begin in the next few month ...

ATHENS, Greece, July 31, 2024 (GLOBE NEWSWIRE) -- Diana Shipping Inc. (NYSE: DSX), (the "Company"), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today reported a net loss of $2.8 million and a net loss attributed to common stockholders of $4.2 million for the second quarter of 2024. This compares to net income of $10.4 million and net income attributed to common stockholders of $8.9 million for the second quarter of 2023. Loss per share for the second ...

文章核心观点 - 美国FDA授予公司的VCN-01用于治疗视网膜母细胞瘤的罕见儿童药物指定[1][2][3] - VCN-01是一种全身性的选择性肿瘤溶解腺病毒,可以多方面抑制肿瘤生长[5] - 公司正在与医生和监管机构密切合作,优化VCN-01在儿童晚期视网膜母细胞瘤中的临床开发策略[2] - 最近一项针对复发性视网膜母细胞瘤的I期临床试验结果显示积极[2] 行业概况 - 视网膜母细胞瘤是儿童最常见的眼部肿瘤,每年在美国约有200-300例新发病例[4] - 保存生命和避免失明等严重后果仍然是一大挑战[4] - 在资源匮乏的国家,儿童视网膜母细胞瘤患者更容易失去眼睛并死于转移性疾病[4] 公司概况 - 公司是一家多元化的临床阶段生物制药公司,专注于开发治疗癌症和相关疾病的新药[6][7] - 公司的主要产品包括VCN-01、SYN-004和SYN-020,涉及多种适应症[6][7] - 如果VCN-01获批上市,公司可能有资格获得优先审评券[3] - 公司目前现金储备可提供到2025年第一季度的运营资金[8]

Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology Fosgonimeton treatment, alone and in combination with lecanemab, protected cultures of primary neurons from the toxic effects of amyloid-β BOTHELL, Wash., July 31, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow n ...